GOUTY ARTHRITIS MARKET ANALYSIS

Gouty Arthritis Market, by Drug Class (NSAIDs, Corticosteroids, Colchicine, and Urate-lowering agents), by Gouty Type (Acute Gouty Arthritis and Chronic Gouty Arthritis) and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI1368
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Major players operating in the gouty arthritis market include AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Novartis AG; Savient Pharmaceuticals, GlaxoSmithKline plc, Merck& Co. Inc., Teijin Pharma Ltd., Regeneron Pharmaceuticals, JW Pharmaceutical Corporation, and Nippon Chemiphar Co. Ltd.

In August 2017, FDA approved first fixed dose combination called Duzallo (Ironwood Pharmaceuticals) of lesinurad with allopurinol to treat hyperuricemia in patients with uncontrolled gout. Duzallo is a one a day combination oral treatment.
In 2015, Prasco Laboratories and Takeda Pharmaceutical Inc. entered into a distribution and supply agreement for the rights to distribute Colchicine Tablets, USP, which is generic version of Colrycs, colchicine brand by Takeda Pharmaceutical Inc., this would strengthen the distribution for colchicine and improve accessibility.
Novartis in 2013 received European commission approval for Ilaris in treatment of acute gouty arthritis for patients who suffer from frequent attacks of gouty arthritis and are contraindicated to use other treatment option. Illaris is first biologic product to be used in gouty arthritis in Europe.